Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 115.31% | -21.07% | -31.14% | 17.34% | -32.41% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -581.04% | 172.43% | 46.17% | -604.02% | 4,762.50% |
| Change in Net Operating Assets | 90.50% | -442.36% | -77.44% | 27.84% | 39.13% |
| Cash from Operations | 28.21% | 2.93% | -17.88% | -72.22% | -10.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -- | 100.00% | -100.23% | 200.23% |
| Cash from Investing | -100.00% | -- | 100.00% | -100.23% | 199.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 370.20% | 3.28% | -17.39% | -180.96% | 152.81% |